In vivo inhibition by a site-specific catalytic RNA subunit of RNase P designed against the BCR-ABL oncogenic products: A novel approach for cancer treatment

Blood

Volumn 95, Issue 3, 2000, Pages 731-737

  Cobaleda, C ^a   Sanchez Garcia I ^a,b  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b Instituto de Biología Funcional y Genómica and Departamento de Microbiología y Genética   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; MESSENGER RNA; RIBONUCLEASE;

ARTICLE; BASE PAIRING; CANCER THERAPY; CATALYSIS; CHROMOSOME ABERRATION; FUSION GENE; GENE EXPRESSION; MOLECULAR RECOGNITION; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; TUMOR CELL;

EID: 0034142211     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.3.731.003k28_731_737     Document Type: Article

References (32)

1. Szczylik C, Skorski T, Nicolaides NC, et al. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science. 1991;253:562.
2. Skorski T, Nieborowska-Skorska M, Nicolaides NC, et al. Suppression of Philadelphia leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc Natl Acad Sci U S A. 1994; 91:4504.
3. Choo Y, Sánchez-García I, Klug A. In vivo repression by a site-specific DNA-binding protein designed against an oncogenic sequence. Nature. 1994;372:542.
4. Sánchez-García I, Rabbitts TH. LIM proteins in leukaemia and development. Semin Cancer Biol. 1993;4:349.
5. Sánchez-García I. Consequences of chromosomal translocations in tumor development. Annu Rev Genet. 1997;31:429.
6. Cobaleda C, Pérez-Losada J, Sánchez-García I. Chromosomal abnormalities and tumor development: from genes to therapeutic mechanisms. Bioessays. 1998;20:922.
7. Zhao RCH, McIvor RS, Griffin JD, Verfaillie CM. Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo. Blood. 1997;90:4687.
8. James HA, Gibson I. The therapeutic potential of ribozymes. Blood. 1998;91:371.
9. Kuwabara T, Warashina M, Tanabe T, Tani K, Asano S, Taira K. A novel allosteric trans-activated ribozyme, the maxizyme, with exceptional specificity in vitro and in vivo. Mol Cell. 1998;2: 617.
10. Forster AC, Altman S. External guide sequence for and RNA enzyme. Science. 1990;249:783.
11. Li Y, Guerrier-Takada C, Altman S. Targeted cleavage of mRNA in vitro by RNAse P from Escherichia coli. Proc Natl Acad Sci U S A. 1992; 89:3185.
12. McClain WH, Guerrier-Takada C, Altman S. Model substrates for an RNA enzyme. Science. 1987;238:527.
13. Liu F, Altman S. Inhibition of viral gene expression by the catalytic RNA subunit of RNase P from Escherichia coli. Genes Dev. 1995;9:471.
14. Liu F, Altman S. Requirements for cleavage by a modified RNaseP of a small model substrate. Nucl Acids Res. 1996;24:2690.
15. Heisterkamp N, Jenster G, Hoeve HT, Zovich D, Pattengale PK, Groffen J. Acute leukemia in bcr/ abl transgenic mice. Nature. 1990;344:251.
16. Konopka JB, Watanabe SM, Witte ON. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase actitvity. Cell. 1984;37:1035.
17. Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukemia. Nature. 1985;315:550.
18. Mes-Masson A-M, McLaughlin J, Daley GQ, Paskind M, Witte ON. Overlapping cDNA clones define the complete coding region for the p210bcr-abl gene product associated with chronic myelogeous leukemia cells containing the Philadelphia chromosome. Proc Natl Acad Sci U S A. 1986;83:9768.
19. 1-positive ALL. Science. 1987;235:85.
20. Daley CG, McLaughlin J, Witte ON, Baltimore D. The CML-specific P210 bcr/abl, unlike v-abl, does not transform NIH/3T3 fibroblasts. Science. 1987; 237:532.
21. Hermans A, Heisterkamp N, von Linden M, et al. Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia. Cell. 1987;51:33.
22. Elefanty AG, Hariharn IK, Cory S. bcr-abl, the hallmark of chronic myeloid leukemia in man, induces multiple haematopoietic neoplasms in mice. EMBO J. 1990;9:1069.
23. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci U S A. 1990;87:6649.
24. Gishizky ML, Johnson-White J, Witte ON. Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome. Proc Natl Acad Sci U S A. 1993;90:3755.
25. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247:1079.
26. Dhut S, Chaplin T, Young BD. Normal c-abl gene protein-a nuclear component. Oncogene. 1991;6: 1459.
27. McWhirter JR, Wang JYJ. Activation of tyrosine kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. Mol Cell Biol. 1991;11:1553.
28. McLaughlin J, Chianese E, Witte ON. Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells. Mol Cell Biol. 1989;9:1866.
29. Sánchez-García I, Grütz G. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc Natl Acad Sci U S A. 1995;92:5287.
30. Palacios R, Steinmetz M. IL-3 dependent mouse clones that express B-220 surface antigen, conlain Ig genes in germ-line configuration, and generate B-lymphocytes in vivo. Cell. 1985;41:727.
31. bcr-abl protein. Proc Natl Acad Sci U S A. 1988;85:9312.
32. p190 cells. Mol Med. 1996;2:125.